InvestorsHub Logo
icon url

Buyfor1sell for2

06/30/20 8:00 AM

#143554 RE: Buyfor1sell for2 #143553

GALT - Galectin Therapeutics Announces Commencement of patient enrollment of the adaptively-designed Phase 2b/3 trial of Belapectin in NASH Cirrhosis (Stock Price: 3.04)